JP2024543107A5 - - Google Patents

Info

Publication number
JP2024543107A5
JP2024543107A5 JP2024529834A JP2024529834A JP2024543107A5 JP 2024543107 A5 JP2024543107 A5 JP 2024543107A5 JP 2024529834 A JP2024529834 A JP 2024529834A JP 2024529834 A JP2024529834 A JP 2024529834A JP 2024543107 A5 JP2024543107 A5 JP 2024543107A5
Authority
JP
Japan
Prior art keywords
chloro
methyl
dichloro
phenyl
naphthyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024529834A
Other languages
English (en)
Japanese (ja)
Other versions
JP7826477B2 (ja
JP2024543107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/061218 external-priority patent/WO2023094965A1/en
Publication of JP2024543107A publication Critical patent/JP2024543107A/ja
Publication of JP2024543107A5 publication Critical patent/JP2024543107A5/ja
Application granted granted Critical
Publication of JP7826477B2 publication Critical patent/JP7826477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024529834A 2021-11-23 2022-11-21 疾患又は障害の治療のためのナフチリジノン誘導体 Active JP7826477B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163282492P 2021-11-23 2021-11-23
US63/282,492 2021-11-23
CN2022128601 2022-10-31
CNPCT/CN2022/128601 2022-10-31
PCT/IB2022/061218 WO2023094965A1 (en) 2021-11-23 2022-11-21 Naphthyridinone derivatives for the treatment of a disease or disorder

Publications (3)

Publication Number Publication Date
JP2024543107A JP2024543107A (ja) 2024-11-19
JP2024543107A5 true JP2024543107A5 (enExample) 2025-08-25
JP7826477B2 JP7826477B2 (ja) 2026-03-09

Family

ID=84370237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529834A Active JP7826477B2 (ja) 2021-11-23 2022-11-21 疾患又は障害の治療のためのナフチリジノン誘導体

Country Status (29)

Country Link
US (2) US12084442B2 (enExample)
EP (2) EP4436662B1 (enExample)
JP (1) JP7826477B2 (enExample)
KR (1) KR20240110040A (enExample)
CN (1) CN118382623A (enExample)
AR (1) AR127698A1 (enExample)
AU (1) AU2022396087A1 (enExample)
CA (1) CA3235682A1 (enExample)
CL (1) CL2024001524A1 (enExample)
CO (1) CO2024006398A2 (enExample)
CR (1) CR20240216A (enExample)
DK (1) DK4436662T3 (enExample)
DO (1) DOP2024000096A (enExample)
EC (1) ECSP24038829A (enExample)
ES (1) ES3054973T3 (enExample)
FI (1) FI4436662T3 (enExample)
HR (1) HRP20251558T1 (enExample)
IL (1) IL312689A (enExample)
JO (1) JOP20240119A1 (enExample)
LT (1) LT4436662T (enExample)
MA (1) MA67325B1 (enExample)
MX (1) MX2024006176A (enExample)
PE (1) PE20241328A1 (enExample)
PL (1) PL4436662T3 (enExample)
PT (1) PT4436662T (enExample)
RS (1) RS67492B9 (enExample)
TW (1) TW202329949A (enExample)
UY (1) UY40025A (enExample)
WO (1) WO2023094965A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260015867A (ko) * 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (en) 1904-11-07 1905-03-14 William Waid Paddock Pressure filter
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6683113B2 (en) 1999-09-23 2004-01-27 Pharmacia Corporation (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
HUP0301335A3 (en) 2000-04-12 2006-02-28 Novartis Ag Combination of organic compounds
DK1537114T3 (da) 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
CN100447142C (zh) 2002-11-18 2008-12-31 诺瓦提斯公司 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP5179174B2 (ja) 2004-05-28 2013-04-10 ノバルティス ファーマ アーゲー アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ[1,5−a]ピリジン誘導体
US7612088B2 (en) 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
CA2568164A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
WO2006005726A2 (en) 2004-07-09 2006-01-19 Speedel Experimenta Ag Heterocyclic compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
US20090156875A1 (en) 2006-04-04 2009-06-18 Takafumi Tomioka Methane separation method, methane separation apparatus, and methane utilization system
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
CA2660701A1 (en) 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
EA200900811A1 (ru) 2006-12-18 2009-12-30 Новартис Аг Имидазолы в качестве ингибиторов альдостеронсинтазы
KR20090090395A (ko) 2006-12-18 2009-08-25 노파르티스 아게 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도
EP2094669A2 (en) 2006-12-18 2009-09-02 Novartis AG 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
RU2009139811A (ru) 2007-03-29 2011-05-10 Новартис АГ (CH) Гетероциклические спиросоединения
HK1201455A1 (en) 2012-01-27 2015-09-04 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2019241311A1 (en) * 2018-06-11 2019-12-19 Northeastern University Selective ligands for modulation of girk channels
KR20230022829A (ko) 2020-03-03 2023-02-16 트웬티에잇-세븐, 인크. Rna 결합 단백질 또는 rna 변형 단백질을 표적으로 하는 화합물
WO2022074567A1 (en) 2020-10-06 2022-04-14 Novartis Ag Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia

Similar Documents

Publication Publication Date Title
US10766890B2 (en) Hepatitis B core protein modulators
US20230019129A1 (en) Hepatitis b core protein allosteric modulators
JP5690715B2 (ja) ケモカイン受容体調節因子
WO2012072033A1 (zh) 取代的2,3-二氮杂萘酮化合物及其用途
CZ20031941A3 (cs) Substituované triazol diaminové deriváty jako inhibitory kináz
KR102345381B1 (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
US10987360B2 (en) Hepatitis B core protein modulators
US20220024900A1 (en) Compounds and Their Use for Reducing Uric Acid Levels
RS56371B1 (sr) Supstituisana tetrahidrokarbazol i karbazol karboksamid jedinjenja koja se koriste kao inhibitori kinaze
TW202102474A (zh) 吡咯化合物
JP2019531326A5 (enExample)
JP2005531526A (ja) Pde7阻害剤としての(4,2−2置換−チアゾール−5−イル)アミン化合物
JP2005526794A (ja) 薬剤
JP2024543107A5 (enExample)
JP2009506040A (ja) オーロラキナーゼのピリミジニル−ピラゾール阻害剤
EP2725024A1 (en) Azole heterocyclic compound, preparation method, pharmaceutical composition and use
EA018984B1 (ru) Производные пиразолона как ингибиторы pde4
JPH0656825A (ja) ベンゾジアゼピン類
US7563905B2 (en) Triazole derivatives and method of using the same to treat HIV infections
JP3229693B2 (ja) ピペラジン誘導体
RU2024116974A (ru) Производные нафтиридинона для лечения заболевания или расстройства
JP3169413B2 (ja) イミダゾール誘導体
DK158000B (da) Analogifremgangsmaade til fremstilling af 3-(substitueret benzoyl)-indolizinderivater
TW202214574A (zh) 經取代之(呔-1-基甲基)脲類、經取代之n-(呔-1-基甲基)醯胺類及其類似物
JP2815218B2 (ja) ピリミジンジオン誘導体、およびそれを含有する抗不整脈剤